

Powered by the Sharekhan 3R Research Philosophy



What has changed in 3R MATRIX Old New RS ↔ RQ ↔ RV ↔

Company details

Market cap:	Rs. 8,17,431 cr
52-week high/low:	Rs. 1,991 / 1,352
NSE volume: (No of shares)	76.0 lakh
BSE code:	500209
NSE code:	INFY
Free float: (No of shares)	361.0 cr

Shareholding (%)

Promoters	14.4
FII	33.3
DII	37.8
Others	14.5

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	0.9	14.1	39.2	36.5
Relative to Sensex	3.4	13.8	28.2	14.6
Sharekhan Research, Bloomberg				

Infosys Ltd

Strong H1, Guidance raised

IT & ITES	ES			Sharekhan code: INFY			
Reco/View: Buy		\leftrightarrow	CMP: Rs. 1,970		70	Price Target: Rs. 2,270	1
	\uparrow	Upgrade	\leftrightarrow	Maintain	\downarrow	Downgrade	

Summary

- Revenue was strong at \$4,894 million, up 3.1% q-o-q in constant currency (CC) terms, nearly in line with our estimate of \$4,897 million.
- EBIT margins was flat q-o-q at 21.1%, missing our expectations of 21.3%. The company closed 21 large deals with TCV of \$2.4 billion, down 41% q-o-q/68% y-o-y.
- FY25 revenue growth guidance raised to 3.75-4.5% from 3-4% in constant currency terms while maintaining OPM guidance for FY25 at 20-22%
- We maintain Buy with revised PT of Rs. 2,270 (valuing at 30x Sep26E EPS). At CMP, the stock trades at 31/27.2x/24.3x its FY25/26/27E EPS.

Infosys reported revenues stood at \$4,894 million, up 3.1% q-o-q/3.3% y-o-y in CC terms, nearly in line with our estimate of \$4,897 million. In dollar terms, revenue grew by 3.7% q-o-q /up 3.8% y-o-y while revenue in rupee terms stood at Rs 40,986 crore, up 4.3% q-o-q/ up 5.1% y-o-y. Growth was broadbased across most verticals led by Manufacturing and Energy. EBIT margins was flat q-o-q at 21.1%, missing our expectations of 21.3% aided by Project maximus and currency depreciation but offset by acquisition related amortisation and variable costs. Net profit stood at Rs 6,516 crore, up 2.3% q-o-q/4.9% y-o-y. The company closed 21 large deals with TCV of \$2.4 billion, down 41% q-o-q/68% y-o-y. Smaller deals, which is less than \$50 million saw a strong double digit growth. The company raised FY25 revenue growth guidance to 3.75-4.5% from 3-4% in constant currency terms while maintaining OPM guidance for FY25 at 20-22%. Financial services segment in the US continues to see discretionary spend increase in capital markets, mortgages, cards and payments. The company reported good momentum in financial services in US and broad-based growth which augurs well for the company. We believe the company is well positioned to capture cost optimization and transformation opportunities given its strength in industry expertise and market leading capabilities in cloud and generative Al. We maintain Buy with a revised price target (PT) of Rs. 2270 (valuing at 30x Sep-26E EPS). At CMP, the stock trades at 31/27.2x/24.3x its FY25/26/27E EPS.

Key positives

- Net headcount additions were 2,456 q-o-q, taking total headcount to 317,788.
- Utilisation rate (excluding trainees) rose by 60 bps q-o-q to 85.90% from 85.3% in Q1FY25.
- The company added 1 client in the \$100 million+ and 2 clients in the \$50 million+ category.

Key negatives

- large deal TCV moderated to \$2.4 billion, down 41% q-o-q/68% y-o-y.
- Attrition (LTM) inched higher by 20 bps q-o-q to 12.9%.

Management Commentary

- Company raised FY25 revenue growth guidance to 3.75-4.5% in constant currency terms and maintained OPM guidance for the year at 20-22%.
- Employee compensation to see increase in two phases effective January 1, 2025 and April 1, 2025.
- Revenue growth guidance has been raised based on the strong performance in H1FY25, broad-based Q2
 performance and double digit growth in small deals.
- Financial services segment in the US continues to see discretionary spend increase, in capital markets, mortgages, cards and payments.
- Company is seeing slowness in the automotive sector in Europe.

Revision in estimates – We have fine-tuned estimates to factor Q2FY25 performance.

Our Call

Valuation – **Maintain Buy with revised price target of Rs 2,270:** Infosys has reported strong H1FY25 performance and raised the guidance for FY25 which is tad lower than expectations. The company reported good momentum in Financial services in US and broad based growth performance which augurs well for the company. We believe the company is well-positioned to capture cost optimization and transformation opportunities given its strength in industry expertise and market leading capabilities in cloud and generative AI. We expect 8.1%/8.6% Sales and PAT CAGR over FY24-27E. We maintain Buy with a revised price target (PT) of Rs. 2,270 (valuing at 30x Sep-26E EPS). At the CMP, the stock trades at 31/27.2x/24.3x its FY25/26/27E EPS.

Key Risks

Rupee appreciation and/or adverse cross-currency movements. The contagion effect of banking crisis, macro headwinds and recession in the US can moderate the pace of technology spending.

Valuation (Consolidated)				Rs cr
Particulars	FY24	FY25E	FY26E	FY27E
Revenue	1,53,671.0	1,62,383.2	1,76,976.1	1,93,853.4
OPM (%)	23.7	23.8	24.1	24.4
Adjusted PAT	26,232.0	26,361.1	30,082.2	33,603.4
% YoY growth	8.9	0.5	14.1	11.7
Adjusted EPS (Rs)	63.4	63.5	72.5	81.0
P/E (x)	31.1	31.0	27.2	24.3
P/B (x)	5.1	5.0	4.7	4.3
EV/EBITDA	21.8	20.4	18.4	16.4
ROE (%)	29.7	29.2	31.4	32.0
ROCE (%)	34.8	34.6	37.0	38.3

Source: Company; Sharekhan estimates



Key result highlights:

- **Strong revenue growth:** Infosys reported CC revenue growth of 3.1% q-o-q/3.3% y-o-y, nearly in-line with our estimates of 3.2 % q-o-q revenue growth in CC terms. In dollar terms revenue grew by 3.7% q-o-q /up 3.8% y-o-y to \$ 4,894 million. Revenue in rupee terms stood at Rs 40,986 crore, up 4.3% q-o-q/ up 5.1% y-o-y. Growth was broad based across regions and across most verticals. Inorganic contribution was 0.8%.
- Margin performance: EBIT margins was flat q-o-q at 21.1%, missing our expectations of 21.3%. Project Maximus and currency depreciation contributed to 80 bps and 10bps improvement respectively which was offset by 30 bps acquisition-related amortization and 60 bps due to variable costs.
- Large deal TCVs: The company closed 21 large deals with TCV of \$2.4 billion of which 41% was net new. It signed seven deals in financial services, three each in communication, manufacturing and others, two in retail and one each in EURS and High Tech and Life Sciences. Region wise, the company signed 12 large deals in America, five in Europe, three in India and one in ROW. Smaller deals which is less than \$50 million had a strong double digit growth.
- **Demand Commentary:** The financial services segment in the US continues to see discretionary spend increase, in capital markets, mortgages, cards and payments. Financial services saw continued growth momentum in Q2 with traction in cost optimization through large outsourcing and transformation opportunities. The company is seeing slowness in the automotive sector in Europe. Barring these verticals, demand trends remain stable with clients continuing to prioritize cost takeout over discretionary initiatives. Consumer spend in the upcoming holiday season to be a lead indicator for future spend decisions. The communication sector outlook is challenging with clients primarily focused on cost reduction and making their investment profitable. Discretionary spend for OEMs are expected to remain under pressure. Energy sector is seeing significant traction in cloud programs with many companies adopting the Cloud and AI strategy.
- **Vertical-wise performance:** Financial Services, Manufacturing, Energy, Lifesciences, Communications and Hitech grew 2.7%/10.9%/5.4%/3.8%/2.1% and 3.8% q-o-q, respectively while Others segment declined by 2.5% q-o-q. Retail was flat q-o-q.
- **Geography-wise performance:** North America, Europe, India and ROW grew 1.2 and /8.9%/ 3.8% and 4.9% q-o-q, respectively.
- **Headcount continues to decline, utilisation improves:** Attrition (LTM) rose by 20 bps q-o-q to 12.9% from 12.7% in Q1FY25. Utilisation rate (including trainees) improved by 60 bps q-o-q to 85.9%. Net Headcount additions were 2,456 q-o-q taking the total headcount to 317,788. The company is on track to onboard 15000-20000 freshers this year.
- Client metrics: The company added 86 clients versus 97 in Q1FY25. The number of active clients increased to 1870 from 1867. Revenue from the top 5, Top 10 and 25 clients grew by 5.4%/ 3.8% and 3.2% q-o-q respectively. The company added 1 client in \$100 million+ and 2 clients in \$50million+ category.
- Cash flow: Free cash flow (FCF) stood at \$839 million, down 23% q-o-q/25% y-o-y. Consolidated cash and investments stood at \$4.63 billion versus \$4.31 billion in O1FY25.



Results (Consolidated) Rs cr **Particulars** Q2FY25 Q2FY24 Q1FY25 Y-o-Y (%) Q-o-Q (%) Revenues (\$ mn) 4,894 4,718 4,714 3.7 3.8 5.1 **Net sales** 40,986 38,994 39,315 4.3 **Direct Costs** 25,865 5.6 4.9 27,314 26,028 **Gross Profit** 13,129 13,287 4.1 2.9 13,672 SG&A 3,863 3,689 3,850 4.7 0.3 **EBITDA** 9,809 9,440 9,437 3.9 3.9 Depr & amort. 1,160 1,166 1,149 -0.5 1.0 **EBIT** 8,649 8,274 8,288 4.5 4.4 Other Income 604 494 733 22.3 -17.6 **PBT** 9,253 8,768 9,021 5.5 2.6 Tax Provision 2,737 2,553 2,647 7.2 3.4 6,516 6,215 6,374 4.8 2.2 Minority interest/Share of associates **Net profit** 6,516 6,212 6,368 4.9 2.3 EO 6,368 **Adjusted net profit** 6,516 6,212 4.9 2.3 Equity capital (FV Rs5/-) 414 414 414 EPS (Rs) 15.7 15.0 15.4 4.6 2.1 Margin (%) **GPM** 33.4 33.7 33.8 -31 -44 **EBITDA** 23.9 24.2 24.0 -28 -7 21.1 2 **EBIT** 21.2 -12 21.1 NPM 15.9 15.9 16.2 -3 -30 Tax rate 29.6 29.1 29.3 46 24

Source: Company; Sharekhan Research


Revenue mix: Geographies, industry verticals, and other operating metrics

	Revenues	Contribution	\$ Grow	/th (%)	CC growth (%)
Particulars	(\$ mn)	(%)	Q-o-Q (%)	Y-o-Y (%)	Y-o-Y (%)
Revenues (\$ mn)	4,894	100	3.8	3.7	3.3
Geographic mix					
North America	2,809	57.4	1.2	-2.6	-2.7
Europe	1,458	29.8	8.9	16.6	15.5
India	152	3.1	3.8	14.8	16.0
Rest of world	475	9.7	4.9	4.8	3.8
Industry verticals					
Financial services	1,331	27.2	2.7	2.6	2.3
Retail	651	13.3	0.1	-9.2	-9.6
Communication	582	11.9	2.1	8.3	7.0
Energy, utilities, resources & services	661	13.5	5.4	10.3	10.9
Manufacturing	768	15.7	10.9	13.9	12.3
Hi tech	392	8.0	3.8	6.4	6.0
Life sciences	357	7.3	3.8	-2.9	-3.5
Others	152	3.1	-2.5	-2.6	-1.2
Clients Contribution					
Top 5 clients	670	13.7	5.4	6.9	
Top 10 clients	1,023	20.9	3.8	8.9	
Top 25 clients	1,698	34.7	3.2	5.6	
Deal Wins					
TCV	2,430	-	-40.5	-68.4	

Source: Company; Sharekhan Research



Infosys' constant-currency revenue growth trend (y-o-y)




Source: Sharekhan Research

EBIT margin (%) trend



Source: Sharekhan Research


Subcontracting costs trend



Source: Sharekhan Research

Sharekhan

BFSI revenue growth trend




Source: Sharekhan Research

Retail revenue growth trend



Source: Sharekhan Research

TCV of deal wins



Source: Sharekhan Research

October 17, 2024 5



Outlook and Valuation

Sector Outlook – Macro headwinds bottoming out, coupled with better earnings visibility.

We anticipate growth momentum to return in FY25 aided by lower base coupled with easing sector headwinds. Though, IT sector has already outperformed Nifty last year, we expect overall outperformance in CY24 as well driven by receding headwinds and better earnings visibility.


■ Company Outlook – Well-positioned to capture opportunities

Infosys services a large number of Fortune 500/Global 500 clients who have strong balance sheets and are able to hold on better amid the economic downturn. Further, Infosys has aggressively invested in digital technologies in the past couple of years to capture a large portion of upcoming digital spends. Given strong relationships with clients and robust execution capabilities, Infosys is well-positioned to capitalise on opportunities from clients' transformation journeys.

■ Valuation – Maintain Buy with revised price target of Rs 2270:

Infosys has reported strong H1FY25 performance and raised the guidance for FY25 which is tad lower than expectations. The company reported good momentum in Financial services in US and broad based growth performance which augurs well for the company. We believe the company is well-positioned to capture cost optimization and transformation opportunities given its strength in industry expertise and market leading capabilities in cloud and generative AI. We expect 8.1%/8.6% Sales and PAT CAGR over FY24-27E. We maintain Buy with a revised price target (PT) of Rs. 2,270 (valuing at 30x Sep-26E EPS). At the CMP, the stock trades at 31/27.2x/24.3x its FY25/26/27E EPS.

One-year forward P/E (x) band



Source: Sharekhan Research

October 17, 2024 6



About company

Founded in 1981, Infosys is the second largest (\$16,311 million in FY2022) IT services company in India in terms of export revenue with headcount of 3.14 lakh employees. BFSI accounts for the largest chunk of revenue (~31% of total revenue), followed by retail, energy and utilities, and communication. Region wise, North America and Europe continue to be the mainstay. Digital revenue continued to have a strong growth momentum in the past few quarters and now contributes 59.2% to total revenue.

Investment theme

Infosys has accelerated deal wins momentum through engagement with deal advisors, consulting firms, and private equity players. Effectively, the strong large deal trajectory provides better revenue growth visibility. Further, revitalisation of sales and investment in digital competencies have certainly helped the company to drive its digital business. Sharp focus on execution and augmentation of digital capabilities through investments can bring Infosys back on its high-growth trajectory. Given strong deal wins, strengthening relationships with large clients, and continued digital momentum, we believe Infosys is well positioned to catch up with leaders on revenue growth in the coming years.

Key Risks

1) Rupee appreciation and/or adverse cross-currency movements. 2)The contagion effect of banking crisis, macro headwinds and recession in the US can moderate the pace of technology spending.

Additional Data

Key management personnel

, ,	
Nandan M. Nilekani	Co-founder and Non-Executive Chairman
Salil Parekh	Chief Executive Officer
Jayesh Sanghrajka	Chief Financial Officer

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Deutsche Bank Trust Co Americas	10.09
2	Life Insurance Corp of India	9.72
3	SBI Funds Management Ltd	4.20
4	Vanguard Group Inc/The	3.48
5	Blackrock Inc	3.46
6	ICICI Prudential Asset Management	2.67
8	NATIONAL PENSION SYSTEM	1.65
9	UTI Asset Management Co Ltd	1.61
10	HDFC Asset Management Co Ltd	1.53
12	Republic of Singapore	1.33

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/ weak realisation environment resulting in margin pressure and detoriating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative Source: Sharekhan Research	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research



DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/ material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. CIN: - U99999MH1995PLC087498.

Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Correspondence/Administrative Office Address - Gigaplex IT Park, Unit No 1001, 10th Floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD) / MCX - Commodity: INZ000171337; BSE - 748, NSE - 10733, MCX - 56125, DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669 (date of initial registration: 03/07/2004, and valid till 02/07/2026); IRDAI Registered Corporate Agent (Composite) License No. CA0950, valid till June 13, 2027.

Compliance Officer: Ms. Binkle R. Oza; Tel: 022-62263303; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022- 41523200/022-69920600.